SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-023147
Filing Date
2018-09-14
Accepted
2018-09-14 16:11:38
Documents
41
Period of Report
2018-07-31

Document Format Files

Seq Description Document Type Size
1 KALV Q1-19 10-Q kalv-10q_20180731.htm 10-Q 739744
2 EX-31.1 kalv-ex311_77.htm EX-31.1 21436
3 EX-31.2 kalv-ex312_75.htm EX-31.2 18693
4 EX-32.1 kalv-ex321_76.htm EX-32.1 8627
  Complete submission text file 0001564590-18-023147.txt   2306140

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT kalv-20180731.xml EX-101.INS 289351
6 XBRL TAXONOMY EXTENSION SCHEMA kalv-20180731.xsd EX-101.SCH 25946
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kalv-20180731_cal.xml EX-101.CAL 35336
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kalv-20180731_def.xml EX-101.DEF 55298
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20180731_lab.xml EX-101.LAB 187540
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20180731_pre.xml EX-101.PRE 137204
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 181071252
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1